CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), anti-Programmed Death-(Ligand)-1 (PD-(L)1) antibodies have revolutionised the treatment of patients with advanced non-small cell lung cancer (NSCLC).